US20150073046A1 - Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands - Google Patents

Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands Download PDF

Info

Publication number
US20150073046A1
US20150073046A1 US14/395,581 US201314395581A US2015073046A1 US 20150073046 A1 US20150073046 A1 US 20150073046A1 US 201314395581 A US201314395581 A US 201314395581A US 2015073046 A1 US2015073046 A1 US 2015073046A1
Authority
US
United States
Prior art keywords
mgs
day
orally
compounds
sigma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/395,581
Inventor
Alexandre Vamvakides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of US20150073046A1 publication Critical patent/US20150073046A1/en
Assigned to ANAVEX LIFE SCIENCES CORP. reassignment ANAVEX LIFE SCIENCES CORP. NOTICE OF RIGHT OF ASSIGNMENT Assignors: VAMVAKIDES, ALEXANDRE, DR.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention involves the original mixed sigma-1/muscarinic ligands: terahydro-N,N-dimethyl-2,2-diphenyl-3-furanomethanamine (AE37), its isomer tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanomethanamine (AE14), their enantiomers and the unique metabolite of AE37, tetrahydro-N-methyl-2,2-diphenyl-3-furanomethanamine (AE37Met) and its enantiomers as -1) optimization agents of the symptomatic treatments, with inhibitors of acetylcholinesterase (IACEases) Donepezil, Galantamine of Rivastigmine, of Alzheimer's disease (AD).
  • IACEases acetylcholinesterase
  • IACEases as the therapeutic drugs, i.e., capable to stop or, at least, to strongly slowing the evolution of Alzheimer's disease (AD). Indeed, in spite of some encouraging effects of Donepezil, Galantamine and Rivastigmine on the symptoms of mild to moderate AD, no significant therapeutic impact of these IACEases on the evolution of AD was obtained and number of clinical studies re-ported worsening of the patients AD treated with the above drugs compared with patients AD treated with placebo.
  • AD Alzheimer's disease
  • AE37, AE37Met, AE14 and their enantiomers were extensively studied and were confirmed as mixed sigma-1/muscarinic ligands which, by their pharmacological (molecular, ex-vivo and in vivo) profile, are indicated as optimization agents of the symptomatic treatments of AD with the aforementioned IACEases.
  • all these aminotetrahydrofurans are antagonists of the M2 and M3 muscarinic receptors which originate the cholinergic side effects of Rivastigmine, Galantamine and Donepezil.
  • AE37 which was clinically studied in Phase Ia, could suppress the aforementioned side effects at 1 to 10 mgs, oral/day or higher dose, if necessary, allowing the use of elevated and efficient doses of all these IACEases.
  • AD neurodegenerative diseases
  • the proposed aminotetrahydrofurans are very selective sigma-1 (vs sigma-2) receptors ligands: AE37 derivatives have not any sigma-2 affinity and AE14 derivatives are, at least, 250 fold more selective for sigma-1 receptors (vs sigma-2).
  • Donepezil was recently studied as putative anticancer drug alone or in synergy with clinically used anticancer drugs.
  • these particularities of Donepezil and specifically its sigma-2 affinity could originate apoptosis of neurons, cancel the positive effects of the drug and explain the absence of therapeutic effect on AD.
  • acetylcholine on presynaptic muscarinic M2 auto-receptors, induced by the IACEases is deleterious for the cholinergic neurons and for all the neuronal systems modulated by the extrasynaptic M2 receptors (especially in AD and in ageing, where these M2 auto-receptors are hyper-activated by neurotoxins and soluble amyloids [4]) and could be the most important factor explaining the absence of the therapeutic effects of these drugs on the evolution of AD and also their weak effects against the AD symptoms.
  • the preferential antagonism of the M2 cholinergic auto-receptors by these aminotetrahydrofurans could be considered as an important positive synergestic factor, in concert with their sigma-1 selective agonistic activity, for the therapeutic valorization of Galantamine, Rivastigmine and Donepezil.
  • mice in mice, no synergy was observed because Donepezil has the two components of AE37 i.e., sigma-1 and cholinergic (via IACEase foe Donepezil and by M2 auto-receptors antagonism for AE37).
  • mice i.e., in AD like conditions
  • the antagonism of auto-receptors M2 appeared decisive in the AE37 potentiating effects developed in concert with a more selective sigma-1 effect, reinforced by AE37), which reflect the anti-neurodegenerative valorization of Donepezil by AE37.
  • NMDA N-Methyl-D-Aspartic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention involves the selected aminotetrahydrofurans AE37, AE37Met, AE14 and their enantiomers as original mixed sigma-1/muscarinic ligands for the optimization of the anticholinesterasic drugs and more specifically of Donepezil, Galantamine or Rivastigmine. Indeed, these aminotetrahydrofurans exhibited M2 and M3 muscarinic antagonisms against the cholinergic adverse effects of these drugs, which constitute the most limitating factor in the use of these drugs against the symptoms of the Alzheimer's disease (AD). Moreover, by their antagonism of the presynaptic muscarinic M2 cholinergic autoreceptors and their very selective sigma-1 agonism they constitute putative agents for the valorization of the anticholinesterasic drugs and more specifically of Donepezil, Galatamine or Rivastigmine from their present status of drugs acting against the symptoms of AD to the perspective of therapeutic agents against the evolution of AD.

Description

  • The present invention involves the original mixed sigma-1/muscarinic ligands: terahydro-N,N-dimethyl-2,2-diphenyl-3-furanomethanamine (AE37), its isomer tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanomethanamine (AE14), their enantiomers and the unique metabolite of AE37, tetrahydro-N-methyl-2,2-diphenyl-3-furanomethanamine (AE37Met) and its enantiomers as -1) optimization agents of the symptomatic treatments, with inhibitors of acetylcholinesterase (IACEases) Donepezil, Galantamine of Rivastigmine, of Alzheimer's disease (AD). And -2) as valorization agents of the IACEases as the therapeutic drugs, i.e., capable to stop or, at least, to strongly slowing the evolution of Alzheimer's disease (AD). Indeed, in spite of some encouraging effects of Donepezil, Galantamine and Rivastigmine on the symptoms of mild to moderate AD, no significant therapeutic impact of these IACEases on the evolution of AD was obtained and number of clinical studies re-ported worsening of the patients AD treated with the above drugs compared with patients AD treated with placebo.
  • Moreover, the positive effects of symptomatic treatments with Donepezil, Galantamine or Rivastigmine, on mild to moderate AD symptoms, were obtained at high oral doses (10 or even 23 mgs/day, for Donepezil, 12 mgs/day, for Rivastigmine, given also at 13.3 mgs/day, by transdermal patch and 24 mgs/day for Galantamine), on memory, thinking or quality of life and were usually accompanied by several cholinergic adverse effects : nausea, vomiting, diarrhea, bradycardia.
  • The aforementioned aminotetrahydrofyrans: AE37, AE37Met, AE14 and their enantiomers, were extensively studied and were confirmed as mixed sigma-1/muscarinic ligands which, by their pharmacological (molecular, ex-vivo and in vivo) profile, are indicated as optimization agents of the symptomatic treatments of AD with the aforementioned IACEases. Indeed, all these aminotetrahydrofurans are antagonists of the M2 and M3 muscarinic receptors which originate the cholinergic side effects of Rivastigmine, Galantamine and Donepezil. More specifically, AE37, which was clinically studied in Phase Ia, could suppress the aforementioned side effects at 1 to 10 mgs, oral/day or higher dose, if necessary, allowing the use of elevated and efficient doses of all these IACEases.
  • All these aminotetrahydrofurans exhibited anti-amnesic effects in the tests of scopolamine, dizocilpine and against the amnesia induced by intracerebral injection of soluble amyloids Aβ25-35, in mice. AE14 exhibited also promnesic activity in the step-down test, on mice.
  • According to the molecular pharmacologic profiles, with the ex-vivo functional tests and the in vivo antagonisms of the aforementioned anti-amnesic effects of these aminotetrahydrofurans, their anti-amnesic activity originated by the synergy between the selective sigma-1 (vs sigma-2) agonistic component of these molecules and their antagonism of the presynaptic M2 muscarinic auto-receptors activating the release of acetylcholine on the M1 postsynaptic muscarinic receptors [1]. These two anti-amnesic components are very important, if associated, in administration with Rivastigmine, Galantamine or Donepezil, for the valorization of the IACEases as therapeutic agents capable to stop or, at least, to strongly slowing the evolution of AD. Indeed, the aforementioned results showed that these aminotetrahydrofurans protected the neurons against the stress induced in the Endoplasmic Reticulum (ERstress), i.e., against protein misfolding, mitochondria dysregulation, generation of neurotoxic species and apoptosis, principally, by their selective sigma-1 (vs sigma-2) agonism in concert with their M2 auto-receptors antagonism, indusing cholinergic release. ER stress occurs normally with ageing and pathologically in neurodegenerative diseases, as AD. Sigma-1 agonistic activity of these aminotetrahydrofurans is, therefore an interesting component for the clinical valorization of the IACEases as therapeutic agents acting against the fatal evolution of AD.
  • Concerning Donepezil, which exhibited a high sigma-1 agonism, the synergy with the aminotetrahydrofurans is interesting in a different viewpoint. The proposed aminotetrahydrofurans are very selective sigma-1 (vs sigma-2) receptors ligands: AE37 derivatives have not any sigma-2 affinity and AE14 derivatives are, at least, 250 fold more selective for sigma-1 receptors (vs sigma-2).
  • The author found intriguing the absence of therapeutic effects of Donepezil against the evolution AD and the existence of worsening reports, as Donepezil was, in the past decade, presented as selective sigma-1 ligand, in addition to its IACEase proper-ties. As he did not found any data on the sigma-2 affinity of Donepezil, he confided this test to CEREP (France) and obtained results suggesting an IC50=250 to 300 nanoM for simga-2 receptors ‘2’. There is mounting evidence that sigma-2 ligands are usually (but not always) proapoptotic and, therefore, putative anticancer drugs. In this context, Donepezil was recently studied as putative anticancer drug alone or in synergy with clinically used anticancer drugs. Another molecular aspect which possibly augmented the risk of pro-apoptotic activity of Donepezil, particularly at high doses, is the similarity it exhibited with Irinotecan, an anticancer drug, in 3D structural studies [3]. In spite of a possible putative use of Donepezil as anticancer drug, these particularities of Donepezil and specifically its sigma-2 affinity could originate apoptosis of neurons, cancel the positive effects of the drug and explain the absence of therapeutic effect on AD.
  • The aforementioned observations suggested that the synergy with the proposed aminotetrahydrofurans are interesting for Donepezil, even in the sigma-1 agonistic domain allowing the obtention of higher sigma-1 selectivity and anti-apoptotic activity.
  • More importantly, the increase of acetylcholine on presynaptic muscarinic M2 auto-receptors, induced by the IACEases (Rivastigmine, Galantamine or Donepezil) is deleterious for the cholinergic neurons and for all the neuronal systems modulated by the extrasynaptic M2 receptors (especially in AD and in ageing, where these M2 auto-receptors are hyper-activated by neurotoxins and soluble amyloids [4]) and could be the most important factor explaining the absence of the therapeutic effects of these drugs on the evolution of AD and also their weak effects against the AD symptoms. Indeed the high concentrations of acetylcholine, induced by the IACEases Galantamine, Rivastigmine and Donepezil, hyper-stimulated the M2 auto-receptors which exerced high inhibition of the released acetylcholine and severe hypo-activity of the presynaptic cholinergic neurons therefore inducing, in a first phase, the diminution of the cholinergic effect on M1 and nicotinic receptors (insufficient symptomatic benefit) and, in a second phase, degeneration of hypoactive cholinergic neurons (absence of therapeutic effects on the evolution of AD and, possibly, even worsening).
  • In this context, the preferential antagonism of the M2 cholinergic auto-receptors by these aminotetrahydrofurans (especially of the AE37 group) could be considered as an important positive synergestic factor, in concert with their sigma-1 selective agonistic activity, for the therapeutic valorization of Galantamine, Rivastigmine and Donepezil.
  • It is noteworthy that in the acute experiments of co-administrations of these aminotetrahydrofurans and Donepezil, in protocols of amnesia, in mice, with scopolamine or dizocilpine, no significant synergistic effects were observed. On the contrary, in the sub-chronic neurodegenerative amnesia, in mice, by intra-cerebral injection of soluble amyloids Aβ25-35, potentiations (i.e., more than synergistic effects) were obtained with AE37 plus Donepezil. These results confirmed that this antagonistic effect on the cholinergic auto-receptors M2 is an important, if not decisive, factor in the valorization of the activity of Donepezil by AE37. Indeed, in the acute scopolamine and Dizocilpine amnesia experiments, in mice, no synergy was observed because Donepezil has the two components of AE37 i.e., sigma-1 and cholinergic (via IACEase foe Donepezil and by M2 auto-receptors antagonism for AE37). However, in the AB25-35 sub-chronic neurodegenerative amnesia, in mice, (i.e., in AD like conditions) the antagonism of auto-receptors M2 appeared decisive in the AE37 potentiating effects developed in concert with a more selective sigma-1 effect, reinforced by AE37), which reflect the anti-neurodegenerative valorization of Donepezil by AE37.
  • Finally, especially for the AE37 derivatives, their anti-NMDA activity (i.e., protection against the glutamatergic toxicity which induced degeneration of neurons via the action of the neurotransmitter glutamic acid on N-Methyl-D-Aspartic acid (NMDA) receptors of the brain) is a putative ameliorating component in the synergistic therapeutic valorization on the IACEases.
    • REFERENCES
    • [1] Alexandre VAMVAKIDES, Brevet d'Invention No 0601577 France, 20 Jul. 2012 and W02008/087458.
    • [2] CEREP Report 100005726, 18 Oct. 2012.
    • [3] Harel M. et al., Mol. Pharmacology: 67. 1874-81, 2005.
  • [4] Liu J. et al., J. Biol. Chem., 284, 19564-71, 2009.

Claims (10)

1. Pharmaceutical use of the original mixed sigma-1muscarinic ligand tetrahydro-N,N-dimethyl-2,2 diphenyl-3-furanomethanamine (AE37), its isomer tetrahydro-N,N-dimethyl-5,5-furanomethanamine (AE14), the unique metabolite of AE37, tetrahydro-N-methyl-2,2-diphenyl-3 -furanomethanamine (AE37Met), their enantiomers and their pharmacologically acceptable salts as optimization agents of the symptomatic treatments of the Alzheimer's disease (AD) by the inhibitors of cholinesterases (IChEases) and also in the valorization of the IChEases as therapeutic drugs against AD.
2. All pharmacological compositions characterized by the fact that they do contain compounds of the claim 1 and, at least, one pharmaceutically acceptable excipient.
3. Pharmaceutical use of the compounds of the claim 1 against the cholinergic adverse effects of the IChEases, in the symptomatic treatment of AD, by the antagonism of the M2 and M3 muscarinic receptors exerced by the compounds of the claim 1.
4. Pharmaceutical use of the compounds of the claim 1 for the valorization of IchEases as therapeutic agents against the evolution of AD, by the antagonism of the pre-synaptic muscarinic M2 autoreceptors in synergy with their sigma-1 selective agonism exersed by the compounds of the claim 1.
5. Pharmaceutical use of the compounds of the claim 1 (orally, 1 to 10 mgs/day) against the adverse cholinergic effects of Donepezil (orally 5, 10 or even 23 mgs/day) in the symptomatic treatment of AD, by their antagonism of the M2 and M3 muscarinic receptors.
6. Pharmaceutical use of the compounds of the claim 1 (orally, 1 to 10 mgs/day) for the valorization of Donepezil (orally, 5, 10 or even 23 mgs/day) as therapeutic drug against the evolution of AD, by their antagonism of the presynaptic muscarinic M2 autoreceptors in synergy with their sigma-1 selective agonism.
7. Pharmaceutical use of the compounds of the claim 1 (orally, 1 to 10 mgs/day) against, the adverse cholinergic effects of Rivastigmine (orally, 6 to 12 mgs/day or transdermal patch 4.6, 9.5 or 13.3 mgs/day), in the symptomatic treatment of AD, by their antagonism of the M2 and M3 muscarinic receptors.
8. Pharmaceutical use of the compounds of the claim 1 (orally, 1 to 10 mgs/day) for the valorization of Rivastigmine (orally, 6 to 12 mgs/day or transdermal patch 4.6, 9.5 or 13.3 mgs/day) as therapeutic drug against the evolution of AD, by their antagonism of the presynaptic muscarinic M2 autoreceptors in synergy with their selective sigma-1 agonism.
9. Pharmaceutical use of the compounds of the claim 1 (orally, 1 to 10 mgs/day) against the adverse cholinergic effects of Galantamine (orally, tablets of 4, 8 or 12 mgs/day or capsules of 8, 16 or 24 mgs/day) in the symptomatic treatment of AD, by their antagonism of the M2 and M3 muscarinic receptors.
10. Pharmaceutical use of the compounds of the claim 1 (orally, 1 to 10 mgs/day) for the valorization of Galantamine, (orally, tablets of 4, 8 or 12 mgs/day or capsules of 8, 16 or 24 mgs/day) as therapeutic drug against the evolution of AD, by their antagonism of the presynaptic muscarinic M2 autoreceptors in synergy with their selective sigma-1 agonism.
US14/395,581 2013-03-28 2013-04-03 Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands Abandoned US20150073046A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR20130100181 2013-03-28
GR20130100181A GR1008233B (en) 2013-03-28 2013-03-28 Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrafurans acting as mixed sigma-1 / muscarinic ligands
PCT/GR2013/000018 WO2014155138A1 (en) 2013-03-28 2013-04-03 Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/GR2013/000018 Continuation-In-Part WO2014155138A1 (en) 2013-03-28 2013-04-03 Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands
PCT/GR2013/000018 A-371-Of-International WO2014155138A1 (en) 2013-03-28 2013-04-03 Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/865,862 Continuation-In-Part US20160009674A1 (en) 2013-03-28 2015-09-25 Prototypical brain protective activity of tetrahydro-n-methyl-2,2-diphenyl-3-furanomethanamine (ae37met)

Publications (1)

Publication Number Publication Date
US20150073046A1 true US20150073046A1 (en) 2015-03-12

Family

ID=48326337

Family Applications (4)

Application Number Title Priority Date Filing Date
US14/395,581 Abandoned US20150073046A1 (en) 2013-03-28 2013-04-03 Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands
US13/940,352 Active 2034-06-24 US9750746B2 (en) 2013-03-28 2013-07-12 ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
US14/865,862 Abandoned US20160009674A1 (en) 2013-03-28 2015-09-25 Prototypical brain protective activity of tetrahydro-n-methyl-2,2-diphenyl-3-furanomethanamine (ae37met)
US15/695,170 Abandoned US20170360798A1 (en) 2013-03-28 2017-09-05 Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/940,352 Active 2034-06-24 US9750746B2 (en) 2013-03-28 2013-07-12 ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection
US14/865,862 Abandoned US20160009674A1 (en) 2013-03-28 2015-09-25 Prototypical brain protective activity of tetrahydro-n-methyl-2,2-diphenyl-3-furanomethanamine (ae37met)
US15/695,170 Abandoned US20170360798A1 (en) 2013-03-28 2017-09-05 Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection

Country Status (3)

Country Link
US (4) US20150073046A1 (en)
GR (1) GR1008233B (en)
WO (1) WO2014155138A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517232B2 (en) 2013-11-02 2016-12-13 Medi Synergics, LLC Compounds for treatment of alzheimer's disease
WO2016064711A1 (en) * 2014-10-20 2016-04-28 Anavex Life Sciences Corp. A 19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy
JP7304043B2 (en) 2015-07-22 2023-07-06 アナベックス ライフ サイエンシズ コーポレイション Crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, methods of making such forms and pharmaceutical compositions thereof
WO2017013496A1 (en) * 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Enantiomers of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine (anavex2-73) and use thereof in the treatment of alzheimer's disease and other disorders modulated by the sigma 1 receptor
GR1009143B (en) * 2016-07-14 2017-10-20 Αλεξανδρος Δημητριου Βαμβακιδης Original therapeutical activity of selected aminotetrahydrofurans against pervasive neurodevelopmental and neurodegenerative diseases
CA3032299C (en) * 2016-07-27 2024-03-05 Anavex Life Sciences Corp. A2-73 as a therapeutic for insomnia, anxiety and agitation
US10426754B2 (en) 2017-06-14 2019-10-01 Anavex Life Sciences Corp. Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease
JP2020523417A (en) * 2017-06-14 2020-08-06 アナベックス ライフ サイエンス コーポレイション ANAVEX2-73 for the treatment of Alzheimer's disease
WO2019023239A1 (en) * 2017-07-25 2019-01-31 William Beaumont Hospital Methods for diagnosing and treating alzheimer's disease
EP3697408A1 (en) * 2017-10-20 2020-08-26 Anavex Life Sciences Corp. Treatment of cardiac dysfunction
CA3096671A1 (en) 2018-04-12 2019-10-17 Anavex Life Sciences Corp. A2-73 crystalline polymorph compositions of matter and methods of use thereof
CA3100897A1 (en) 2018-05-18 2019-11-21 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
US20220249427A1 (en) * 2019-07-22 2022-08-11 Anavex Life Sciences Corp. Anavex2-73 for the treatment of genetic neurodevelopmental disorders
EP4124338A1 (en) 2021-07-30 2023-02-01 Université de Montpellier Sigma-1 receptor activator for use in the treatment of a pathology associated with wfs1 mutation
WO2024026480A1 (en) * 2022-07-29 2024-02-01 Anavex Life Sciences Corp. Compositions and methods for prevention of cognitive decline caused by degenerative diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115113A (en) * 1995-08-31 2002-11-10 Israel State 3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
GR1005865B (en) 2007-01-17 2008-04-07 Anavex Life Sciences Corp. NEW SIGMA LIGANDS with anti-apoptotic and/or pro-apoptotic action on the cells biochemical mechanisms and neuroprotective, anti-cancer, anti-metastatic, and anti-chronic inflammatory properties.
US7786171B2 (en) * 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The anti-amnesic and neuroprotective effects of donepezil against amyloid b25-35 peptide-induced toxicity in mice involve an interaction with the σ1 receptor. British Journal of Pharamcology (2006) 149 998-1012. *

Also Published As

Publication number Publication date
WO2014155138A1 (en) 2014-10-02
US20160009674A1 (en) 2016-01-14
GR1008233B (en) 2014-06-23
US9750746B2 (en) 2017-09-05
US20140296211A1 (en) 2014-10-02
US20170360798A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
US20150073046A1 (en) Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligands
J Geldenhuys et al. Rationally designed multi-targeted agents against neurodegenerative diseases
Zhang et al. Multi-target design strategies for the improved treatment of Alzheimer's disease
Sharma Cholinesterase inhibitors as Alzheimer's therapeutics
Singh et al. A review on ferulic acid and analogs based scaffolds for the management of Alzheimer’s disease
Singh et al. Hybrids: a new paradigm to treat Alzheimer’s disease
Sonkusare et al. Dementia of Alzheimer’s disease and other neurodegenerative disorders—memantine, a new hope
Freret et al. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice
BR112015029512A8 (en) pyrazolopyrrolidine derivatives, their uses, and pharmaceutical composition and combination
BR112017006957A2 (en) pharmaceutical formulations for the oral release of peptide or protein type drugs
JP2019515891A (en) Composition containing tannic acid and use thereof
Busquet et al. Synergistic effects of galantamine and memantine in attenuating scopolamine-induced amnesia in mice
MX2018008021A (en) Methods and compositions for the treatment of seizure-related disorders.
JP2013518914A5 (en)
BR112016007016A8 (en) compound or a pharmaceutically acceptable salt thereof, use of a compound, and pharmaceutical composition
Thangnipon et al. N-benzylcinnamide protects rat cultured cortical neurons from β-amyloid peptide-induced neurotoxicity
JP2016514688A5 (en)
Lütjens et al. Recent advances in drug discovery of GPCR allosteric modulators for neurodegenerative disorders
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
Misik et al. Effects of novel tacrine-related cholinesterase inhibitors in the reversal of 3-quinuclidinyl benzilate-induced cognitive deficit in rats—Is there a potential for Alzheimer’s disease treatment?
Dubey et al. Antioxidants: An approach for restricting oxidative stress induced neurodegeneration in Alzheimer’s disease
BR112019007863A2 (en) innovative naphthyridinone derivatives and their use in the treatment of arrhythmia
US20150126611A1 (en) 3,3-diphenyl-n-(1-phenylethyl) propan-1-amine: as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytoprotective) properties and prototypical anticancer activity
Fleck et al. Investigation into the in vivo effects of five novel tacrine/ferulic acid and β-carboline derivatives on scopolamine-induced cognitive impairment in rats using radial maze paradigm
Pasieka et al. Multifunctional Ligand Approach: search for Effective Therapy Against Alzheimers Disease

Legal Events

Date Code Title Description
AS Assignment

Owner name: ANAVEX LIFE SCIENCES CORP., NEW YORK

Free format text: NOTICE OF RIGHT OF ASSIGNMENT;ASSIGNOR:VAMVAKIDES, ALEXANDRE, DR.;REEL/FRAME:038491/0380

Effective date: 20160421

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION